StageGrant - II | Dead
Developer of methodologies for the introduction of molecules into viable cells and the repair of genetic defects. The company's technology enables the transfer of genetic material into cells, working a wide variety of mammalian cells, including mono-layers and suspensions, with high transfection rates and minimal cell mortality. The company's technology can transfect a particular cell type out of a mixture of cells and takes around three to six hours to transfect cells. The company's technology also enables other macromolecules such as proteins to enter cells.
Missing: IPBio's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: IPBio's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
IPBio Frequently Asked Questions (FAQ)
When was IPBio founded?
IPBio was founded in 1998.
What is IPBio's latest funding round?
IPBio's latest funding round is Grant - II.
How much did IPBio raise?
IPBio raised a total of $1M.
Who are the investors of IPBio?
Investors of IPBio include Dept of Trade & Industry, Iceni Seedcorn Fund and Cambridge Research & Innovation.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.